Safety Assessment of DBLUS System in Adolescent and Adult Patients With Type 1 Diabetes and Assessment of Its Clinical Efficacy (DIABELOOP SP8)

Diabetes Mellitus, Type 1 Clinical Trial

— DIABELOOP SP8  

Official title:

Safety Assessment of DBLUS System in Adolescent and Adult Patients With Type 1 Diabetes and Assessment of Its Clinical Efficacy in a Randomized Trial for 3 Months Followed by an Extension Period

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04190277
• Other study ID #: 2019-A01975-52
• Status: Terminated
• Phase: N/A
• Start date: January 7, 2020
• Est. completion date: June 16, 2020

Study information

• Verified date: April 2021
• Source: Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial is a randomized trial including a 3-month single-arm part and a 6-month extension phase.

• Following randomization between the 1st group and 2nd group, a 2-week baseline period in open-loop for 148 adults and 30 adolescents will be performed. Patients will receive the standard of care treatment including their usual subcutaneous insulin pump augmented with continuous glucose measurement with Dexcom G6.

• Then, a 3-month study phase will be performed during 12 weeks:

• 1st group (111 adults randomized from 148 adults and 30 adolescents) will receive the treatment via the Closed-loop System (closed-loop condition).

• 2nd group (37 adult controls randomized from 148 adults) will receive the standard of care treatment including their usual subcutaneous insulin pump augmented with continuous glucose measurement with Dexcom G6 (open loop condition).

• An extension period of 6 months with the Closed-loop System (closed-loop condition) will be performed at the end of the study phase for all patients enrolled.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 184
• Est. completion date: June 16, 2020
• Est. primary completion date: March 16, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 14 Years to 75 Years

Eligibility

Inclusion Criteria:

• age 14 - 75 years at time of screening

• Type 1 diabetes

• Subject has a clinical diagnosis of type 1 diabetes for at least 2 years as determined via medical records or source documentation by an individual quali?ed to make a medical diagnosis.

• An insulin pump user for at least 6 months (with or without CGM experience),

• Living in an area covered by a GSM (Global System for Mobile Communications) network

• Patient not isolated, does not live alone, or has a person living nearby who has a telephone and a key to his or her home

• Patient willing to wear the system continuously throughout the study

• Has TSH in the normal range

• if subject has celiac disease, it has been adequately treated as determined by the investigator

• With history of cardiovascular event 1 year or more from the time of screening must have an EKG within 6 months prior to screening and a stress test within 6 months prior to screening or during screening. If subject has an abnormal stress test, he will not be allowed to participate in the study, unless there is clearance from a cardiologist. If subject fails stress test, participation is allowed only if there is clearance from a cardiologist

• With 3 or more cardiovascular risk factors listed below must have an EKG within 6 months prior to screening or during screening. If subject has an abnormal EKG, participation is allowed if there is clearance from a cardiologist. Cardiovascular risk factors include:

• Age >35 years

• Type 1 diabetes of >15 years' duration

• Presence of any additional risk factor for coronary artery disease

• Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)

• Presence of peripheral vascular disease

• Presence of autonomic neuropathy

• Must be able to speak and be literate in French

• For adults (18 - 75 years old): having provided written informed consent

• For adolescents (14 - 17 years old): having provided written assent & parents/guardian having provided written informed consent

Exclusion Criteria:

• Patient receiving a total daily dose of insulin lower than 8 U

• Patient with a daily dose of insulin required greater than 90 units

• Patient having severe problems of uncorrected hearing and/or visual acuity

• Patient unable to understand and perform all of the instructions provided by Diabeloop SA

• Subject is unable to tolerate tape adhesive around the sensor or pump placements

• Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)

• Has had any of the following cardiovascular events within 1 year of screening:

myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease

• Is being treated for hyperthyroidism at time of screening

• Has diagnosis of adrenal insufficiency

• Has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from time of screening visit, or plans to take any oral, injectable, or IV steroids during the study

• Females who are sexually active and able to conceive will be excluded if they are not using an effective method of contraception and do not agree to continue using an effective method of contraception for the duration of the study as determined by investigator.

• Actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 2 weeks

• Currently abusing illicit drugs

• Currently abusing marijuana

• Currently abusing prescription drugs

• Currently abusing alcohol

• Subject is using pramlintide (Symlin), DDP-4 inhibitor, liraglutide (Victoza or other GLP-1 agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening

• Subject has elective surgery planned that requires general anesthesia during the study

• Has a sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion or erythropoietin within 3 months prior to time of screening

• Plans to receive red blood cell transfusion or erythropoietin over study participation

• Diagnosed with current eating disorder such as anorexia or bulimia

• Diagnosed with chronic kidney disease that results in chronic anemia

• Hematocrit that is below the normal reference range of lab used

• Patient who has had a pancreatectomy or who has pancreatic malfunctions

• Patient with pancreatic islet transplantation or pancreas transplantation

• Patient on dialysis

• Patient with impaired hepatic functions

• Serum creatinine > 176 µmol/L

• Any other physical or psychological disease, or medication likely to interfere with the conduct of the study and interpretation of the study results as judged by the investigator.

• Pregnancy

Related Conditions & MeSH terms

• Closed-Loop
• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Device:
• Open-loop condition
Patient's standard insulin pump setting combined with continuous glucose monitoring sensor
• Closed-loop condition
Closed-loop algorithm system paired with continuous glucose monitoring sensor

Locations

Country	Name	City	State
France	Caen University Hospital	Caen
France	Sud Francilien Hospital	Corbeil-Essonnes
France	Grenoble University Hospital	Grenoble
France	Marseille - La Conception University Hospital	Marseille
France	Necker-Enfants Malades University Hospital	Paris
France	Reims University Hospital	Reims
France	Strasbourg University Hospital	Strasbourg
France	Toulouse - Purpan University Hospital	Toulouse
France	Toulouse - Rangueil University Hospital	Toulouse

Sponsors (1)

Lead Sponsor	Collaborator
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence rate of Serious Adverse Device Effect occuring during the 12-week closed-loop period		12-weeks closed-loop period
Primary	Percentage of time spent in hypoglycemia (glucose level below 70mg/dL (3.9 mmol/L)) between baseline period (2-week period) and in-home study phase in closed-loop (12-week period) for the whole patients of the "single-arm" part	as recorded by continuous subcutaneous glucose monitoring (CGM)	14-week baseline & closed-loop period
Primary	Difference in percentage of time spent in hypoglycemia (<70mg/dL) during 12 weeks between closed-loop and open-loop	as recorded by continuous subcutaneous glucose monitoring (CGM)	12-week period
Secondary	Percentage of sensor time in glucose level o < 50mg/dL (2.8 mmol/L) o < 60 mg/dL (3.3 mmol/L) o < 70mg/dL (3.9 mmol/L)	measured by the Dexcom G6 CGM	during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am throughout the 38-week study
Secondary	Number of hypoglycemic episodes with beginning and end of episode o < 70 mg/dL (3.9 mmol/L) o = 54 mg/dL (3 mmol/L)	as measured by the Dexcom G6 CGM	36-week period
Secondary	Incidence of severe hypoglycemia: o Number of severe hypoglycemic episodes needing a third-party intervention o Number of severe hypoglycemic episodes with loss of consciousness o Number of hospitalizations because of a severe hypoglycemia episode		36-week period
Secondary	Number of severe hyperglycemia episodes with beginning and end of episode : o > 350 mg/dL (19.4 mmol/L) o > 360 mg/dL (20 mmol/L) or significant ketosis (plasmatic ketones > 3 mmol/L) as defined by the ADA.	as measured by the Dexcom G6 CGM	36-week period
Secondary	Incidence of severe hyperglycemia: o Number of hospitalizations because of ketoacidosis (i.e. incidence of DKA)		36-week period
Secondary	Number of technical incidents leading to the interruption of the closed loop		36-week period
Secondary	Number of serious adverse events, serious adverse device events, unanticipated adverse device effects		36-week period
Secondary	Area under the curve (AUC) from CGM analysis		36-week period
Secondary	Risk of hypoglycemia and hyperglycemia (LBGI/HBGI)	Low Blood Glucose Interstitial & High Blood Glucose Interstitial as measured by the Dexcom G6 CGM	36-week period
Secondary	Percentage of time spent in the 70-180 mg/dL target range	as recorded by continuous subcutaneous glucose monitoring (CGM)	during 12 weeks during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am throughout the 38-week study
Secondary	Percentage of time spent in the 70-180 mg/dL target range	as recorded by continuous subcutaneous glucose monitoring (CGM)	during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am throughout the 38-week study
Secondary	Percentage of sensor time in glucose level : o < 50 mg/dL (2.8 mmol/L), o < 54 mg/dL (3.0 mmol/L) o < 60 mg/dL (3.3 mmol/L), o < 70 mg/dL (3.9 mmol/L)	as recorded by continuous subcutaneous glucose monitoring (CGM)	during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am throughout the 38-week study
Secondary	Percentage of sensor time in glucose range 54-70 mg/dL (3.0 - 3.9 mmol/L)	as recorded by continuous subcutaneous glucose monitoring (CGM)	during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am throughout the 38-week study
Secondary	Percentage of sensor time in glucose range 70-140 mg/dL (3.9 - 7.8 mmol/L)	as recorded by continuous subcutaneous glucose monitoring (CGM)	during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am throughout the 38-week study
Secondary	Percentage of sensor time in glucose level o > 180 mg/dL (10.0 mmol/L), o > 250 mg/dL (13.9 mmol/L), o > 300 mg/dL (16.7 mmol/L) o > 350 mg/dL (19.4 mmol/L)	as recorded by continuous subcutaneous glucose monitoring (CGM)	during nights, for 24 hours (12:00am-12:00am) and during the following periods: from 12:00am to 6:00am, from 6:00am to 12:00am throughout the 38-week study
Secondary	Evolution of glycosylated hemoglobin between inclusion and end of study	calculated from CGM data and measured by blood sampling	at inclusion, after 12-week period, after 24-week extension period
Secondary	Average glycemia level during the entire period	as measured by the Dexcom G6 CGM	36-week period
Secondary	Average fasting glycemia level at 6:00 am	as measured by the Dexcom G6 CGM	36-week period
Secondary	Variability of the glycemia level measured by o the glycemic variation coefficient (CV) intra patient: • CV < 36% • CV = 36% o Standard deviation (SD)		36-week period
Secondary	Average dose of insulin used & its daily evolution during the entire study duration		36-week period
Secondary	Evolution over time of the DBLUS system's performance on a day-to-day and determination of the optimization delay of glycemic control		36-week period
Secondary	Percentage of time spent in closed loop mode (i.e. DBLUS System with loop mode operating)		36-week period
Secondary	Percentage of time spent in operating mode for the Dexcom G6 CGM		36-week period
Secondary	Scoring of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) to evaluate the acceptance		after baseline period (2-week); after12-week-period; after 24-week extension period
Secondary	Scoring of the Diabetes Quality of Life (DQOL) questionnaire to evaluate the acceptance		after baseline period (2-week); after12-week-period; after 24-week extension period
Secondary	Scoring of the Hypoglycemia Fear Survey (HFS) questionnaire to evaluate the acceptance		after baseline period (2-week); after12-week-period; after 24-week extension period
Secondary	Evolution of the weekly average number of CHO intake (for patient with closed-loop)		36-week period
Secondary	Questionnaire of usability (for 50 subjects from Arm 1, including 15 adolescents and 35 adults)		after 4 weeks of closed-loop; after 12 weeks of closed-loop